3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
12
Venous Thrombosis
9
Pulmonary Embolism
9
Neoplasms
8
Thrombosis
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lung Neoplasms
3
Thromboembolism
2
Neoplasm Metastasis
2
Lymphoma
2
Hemorrhage
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Interventions
Cisplatin
109
Radiotherapy
100
Fluorouracil
90
Paclitaxel
75
Oxaliplatin
63
Docetaxel
56
Carboplatin
55
Irinotecan
41
Esophagectomy
41
Leucovorin
40
Capecitabine
39
Surgical Procedures, Operative
36
Radiation
36
Drug Therapy
31
Neoadjuvant Therapy
25
Chemoradiotherapy
18
Cetuximab
18
S 1 (combination)
17
pembrolizumab
16
camrelizumab
16
Nivolumab
15
Magnetic Resonance Spectroscopy
15
Bevacizumab
15
Blood Specimen Collection
14
Surveys and Questionnaires
12
Radiotherapy, Intensity-Modulated
12
Immunotherapy
11
Epirubicin
11
Biopsy
11
Trastuzumab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Neoplasms
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled